Salem Investment Counselors Inc. Has $6.93 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Salem Investment Counselors Inc. reduced its stake in Thermo Fisher Scientific by 9.3% during Q2, now holding shares worth approximately $6.93 million.
• Institutional investors own 89.23% of Thermo Fisher Scientific, with several firms, including Mondrian Investment Partners LTD and GAMMA Investing LLC, increasing their stakes significantly in the recent quarter.
• Thermo Fisher reported a strong quarterly performance with an EPS of $5.36, beating analyst expectations and setting Q3 2025 guidance at 5.460-5.510 EPS.

Salem Investment Counselors Inc. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,074 shares of the medical research company's stock after selling 1,748 shares during the period. Salem Investment Counselors Inc.'s holdings in Thermo Fisher Scientific were worth $6,925,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mondrian Investment Partners LTD increased its stake in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after buying an additional 127,357 shares during the last quarter. GAMMA Investing LLC increased its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after buying an additional 877 shares during the last quarter. Advisors Capital Management LLC increased its stake in Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock valued at $63,201,000 after buying an additional 7,967 shares during the last quarter. United Services Automobile Association acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at $4,395,000. Finally, Ilmarinen Mutual Pension Insurance Co increased its stake in shares of Thermo Fisher Scientific by 5.3% during the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock worth $33,488,000 after purchasing an additional 3,400 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $479.48 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The company has a 50-day simple moving average of $466.86 and a 200 day simple moving average of $451.08.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Ratings Changes

Several research firms have recently weighed in on TMO. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Finally, Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.